Get started
Author

Lorenzo Pilla

Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine
2007 · Paola Filipazzi, Roberta Valenti, et al. · Journal of Clinical Oncology · 653
Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with Transforming Growth Factor-β–Mediated Suppressive Activity on T Lymphocytes
2006 · Roberta Valenti, Veronica Huber, et al. · Cancer Research · 517
PDF
Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings
2002 · Filiberto Belli, Alessandro Testori, et al. · Journal of Clinical Oncology · 387
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
2006 · G. Parmiani, C. Castelli, et al. · Annals of Oncology · 300
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
2012 · Anna Maria Di Giacomo, Paolo A Ascierto, et al. · The Lancet Oncology · 288
IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells
2004 · Cristina Tecchio, Veronica Huber, et al. · Blood · 168
PDF
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
2014 · A.M. Di Giacomo, P.A. Ascierto, et al. · Annals of Oncology · 139
PDF
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients
2005 · Lorenzo Pilla, Roberto Patuzzo, et al. · Cancer Immunology Immunotherapy · 138
Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-α Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors
2006 · Tiziana Di Pucchio, Lorenzo Pilla, et al. · Cancer Research · 122
PDF
Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells
2003 · Licia Rivoltini, Chiara Castelli, et al. · The Journal of Immunology · 119
PDF
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort
2023 · Julien Taïeb, Lina Sayah, et al. · European Journal of Cancer · 107
Role of Cross-Talk between IFN-α-Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens
2004 · Diego Tosi, Roberta Valenti, et al. · The Journal of Immunology · 97
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
2020 · Sara Massironi, Lorenzo Pilla, et al. · Cells · 88
PDF
Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
2012 · Paola Filipazzi, Lorenzo Pilla, et al. · Clinical Cancer Research · 76
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?
2005 · Licia Rivoltini, Paola Canese, et al. · Expert Opinion on Biological Therapy · 74
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
2024 · Jean-Luc Van Laethem, Ivan Borbath, et al. · The Lancet Oncology · 67
Multipeptide vaccination in cancer patients
2009 · Lorenzo Pilla, Licia Rivoltini, et al. · Expert Opinion on Biological Therapy · 60
Heat Shock Proteins and Their Use as Anticancer Vaccines
2004 · Giorgio Parmiani, Alessandro Testori, et al. · Clinical Cancer Research · 60
Natural Killer andNK-LikeT-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96
2005 · Lorenzo Pilla, Paola Squarcina, et al. · Cancer Research · 46
PDF
MSI colorectal cancer, all you need to know
2022 · Clémence Flecchia, Aziz Zaanan, et al. · Clinics and Research in Hepatology and Gastroenterology · 40
Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
2018 · Anna Tessari, Lorenzo Pilla, et al. · The Breast · 39
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response
2013 · Chiara Camisaschi, Paola Filipazzi, et al. · Cancer Immunology Immunotherapy · 38
PDF
Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
2003 · Matteo G Carrabba, Chiara Castelli, et al. · PubMed · 38
Vaccination of patients with solid tumours
2003 · G. Parmiani, L. Pilla, et al. · Annals of Oncology · 35
Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy
2007 · Giorgio Parmiani, Vincenzo Russo, et al. · Clinical Cancer Research · 34
Works count: 97
Citation count: 4,232
H-index: 29
I10-index: 43
Year
Topic
Type